We've had historically a decline price due to discounting, but I am happy to report that we took our first price increase every on May 1, so in Q3, we expect to see net price program starting to turn around and begin to grow, and so we'll have a nice multiplicative effect on our Feraheme sales, and so Feraheme is our flagship brand. We've got about 70 people across the U.S. who are selling Feraheme.
We've also have announced some recent approvals internationally in Europe, Canada and just last week in Switzerland, and so we will be seeing launches in double-digit royalties and milestones flowing to AMAG on the international basis. On top of that, we are building a company focused on the oncology/hematology in hospital space, which is where call on today in order to promote Feraheme, so we are looking to build out the portfolio with the purchaser in-licensing of commercial assets to leverage those call points.
The company on a whole will breakeven in 2012. For the first time, we will breakeven primarily or at least partially due to $33 million in milestones, so as we go forward and look to 2013, there's a $33 million GAAP if you like, but with sales continuing to grow, operating expenses continuing to decline, we like the idea of adding in an additional marketed asset or two in order to leverage the existence of this high-powered commercial team that we have out there and make the crossover into profitability, so that's really what we are focused on.
Feraheme is number one priority. It's continuing to grow. Feraheme in terms of grams and into profitability, so that's really what we are focused at Feraheme is number one priority. It's continuing to grow Feraheme in terms of grams, and that selling price and second is the successful business development initiative to identify commercial assets with strong IP and preferably in in-office injectable, so that we can leverage our current sales force and cross-over into profitability.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV